Immunotherapy in Melanoma

>

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Latest News

Elizabeth I. Buchbinder, MD
Retrospective Study Shows Nivolumab Associated With OS Benefit After Nivolumab/Ipilimumab irAEs in Advanced Melanoma

November 4th 2023

Elizabeth I. Buchbinder, MD, discusses findings from a retrospective study evaluating the resumption of nivolumab maintenance therapy in patients with advanced melanoma who discontinued treatment with the combination of nivolumab and ipilimumab due to immune-related adverse effects.

Jeffrey Weber, MD, PhD
mRNA-4157 Plus Pembrolizumab Bolsters RFS in Resected Melanoma

October 23rd 2023

FDA
FDA Approves Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

October 14th 2023

UV1 Plus Pembrolizumab in Melanoma | Image Credit:  © SciePro - stock.adobe.com
First-Line UV1 Vaccine Plus Pembrolizumab Sustains OS in Unresectable or Metastatic Melanoma

October 12th 2023

Peter Mohr, MD
Adjuvant Nivolumab Approved in Europe for Completely Resected Stage IIB or IIC Melanoma

August 22nd 2023

Video Series
Video Interviews
Podcasts

More News